Patrick L. Shannon, M.D.
Specialist
- Medicare participating
At a glance
- Medical school
- Northeastern Ohio University College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,003
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Northeastern Ohio University College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
OH license 35076264S
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Optima Dermatology LLC (75 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,003
- Services billed
- 5,648
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,473 | 279 |
| Established patient office or other outpatient visit, 20-29 minutes | 780 | 589 |
| Destruction of precancer skin growth, 1 growth | 481 | 369 |
| Pathology examination of tissue using a microscope, intermediate complexity | 346 | 222 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 276 | 213 |
| Destruction of skin growth, 1-14 growths | 212 | 186 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 115 | 105 |
| Established patient office or other outpatient visit, 30-39 minutes | 101 | 92 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 86 | 70 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 85 | 72 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 74 payments worth $2,437 in total to this clinician.
| AbbVie Inc. | $397 |
|---|---|
| Janssen Biotech, Inc. | $322 |
| Incyte Corporation | $255 |
| Arcutis Biotherapeutics, Inc. | $200 |
| Genzyme Corporation | $196 |
| Sun Pharmaceutical Industries Inc. | $171 |
| Journey Medical Corporation | $164 |
| Organon LLC | $113 |
| Food and Beverage | $2,394 |
|---|---|
| Education | $42.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 29, 2025 | Education TREMFYA · Immunology · in-kind | $42.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $1,160,524 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Inc. - A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
Novartis Pharmaceuticals Corporation - A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
Eli Lilly and Company - A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
Amgen Inc. - Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi US Services Inc. · Recruiting · NCT05263206 - A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopi…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affec…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.